We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
---|---|---|---|---|---|
Immunodiagnostic Systems Holdings Plc | LSE:IDH | London | Ordinary Share | GB00B01YZ052 | ORD 2P |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.00 | 0.00% | 378.00 | 0.00 | 01:00:00 |
Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
---|---|---|---|---|---|
0 | 0 | N/A | 0 |
TIDMIDH
RNS Number : 5505W
Immunodiagnostic Systems Hldgs PLC
01 August 2018
Immunodiagnostic Systems Holdings plc
Transaction in Own Shares
01 August 2018
Immunodiagnostic Systems Holdings plc (IDH.L) ("IDS" or the "Company"), a specialist producer of manual and automated diagnostic testing kits and instrumentation for the clinical and research markets, announces that it has purchased (through Peel Hunt LLP acting as the Company's broker) the following number of its shares of 2p each on the London Stock Exchange. The purchased shares will be held as treasury shares.
The purchases were made pursuant to the buy-back programme announced on 21 June 2017.
Date of purchase: 01 August 2018 Number of shares purchased (aggregated volume): 110 Highest price paid per share (pence): 232.4 Lowest price paid per share (pence): 232.4 Volume weighted average price paid per share (pence): 232.4
Following the purchase of these shares, IDS holds 65,651 ordinary shares as treasury shares and the Company's issued share capital (excluding shares held as treasury shares) consists of 29,384,524 shares. All of the shares have equal voting rights. This figure 29,384,524 represents the total voting rights in the Company and may be used by shareholders as the denominator for the calculations by which they can determine if they are required to notify their interest in, or a change to their interest in, the Company under the Financial Conduct Authority's Disclosure and Transparency Rules.
In accordance with Article 5(1)(b) of Regulation (EU) No 596/2014 (the Market Abuse Regulation), detailed information about the individual purchases made by Peel Hunt on the Company's behalf is set out in the schedule below.
For further information:
Immunodiagnostic Systems Holdings Tel : +44 (0)191 519 0660 plc Paul Martin, Group Finance Director Peel Hunt LLP Tel : +44 (0)207 418 8900 James Steel Oliver Jackson
Schedule of Purchases - Individual Transactions
Number of shares purchased Transaction price Time of transaction Trading venue (pence per share) 110 232.4 13:42:12 London Stock Exchange
This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
END
POSDFLFBVVFBBBZ
(END) Dow Jones Newswires
August 01, 2018 13:06 ET (17:06 GMT)
1 Year Immunodiagnostic Systems Chart |
1 Month Immunodiagnostic Systems Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions